Portale Epatite e malattie del fegato
Sito Epatite B
Sito Steatosi
Sito Cirrosi
Sito Tumori
Sito Trapianti
Nuovi Farmaci
Malattie autoimmuni

Studi scientifici principali



    1. EXPEDITION-4: EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR (ABT-493/ABT-530) IN PATIENTS WITH RENAL IMPAIRMENT AND CHRONIC HEPATITIS C VIRUS GENOTYPE 1 - 6 INFECTION - Ed Gane et al. - AASLD 2016 Nov 11-15 Boston, MA

    2. ENDURANCE-1: A Phase 3 Evaluation of the Efficacy and Safety of 8- versus 12-week Treatment with Glecaprevir/Pibrentasvir (formerly ABT-493/ABT-530) in HCV Genotype 1 Infected Patients with or without HIV-1 Co-infection and without Cirrhosis  - Stefan Zeuzem et al - AASLD 2016 Nov 11-15 Boston, MA

    3. ENDURANCE-3: SAFETY AND EFFICACY OF GLECAPREVIR/PIBRENTASVIR COMPARED TO SOFOSBUVIR PLUS DACLATASVIR IN TREATMENT-NAÏVE HCV GENOTYPE 3-INFECTED PATIENTS WITHOUT CIRRHOSIS - Graham R Foster et al. -The International Liver Congress (EASL) - Amsterdam, The Netherlands 21 April 2017

    4. SURVEYOR-II, PART 3: EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR (ABT-493/ABT-530) IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 3 INFECTION WITH PRIOR TREATMENT EXPERIENCE AND/OR CIRRHOSIS - David Wyles et al. - AASLD 2016 Nov 11-15 Boston, MA

    5. SURVEYOR-II, Part 4: Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients With HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis Following an 8-Week Treatment Duration - Tarek Hassanein et al. - AASLD 2016 Nov 11-15 Boston, MA

    6. HIGH EFFICACY OF ABT-493 AND ABT-530 IN HCV GENOTYPE 1-INFECTED PATIENTS WHO HAVE FAILED DIRECT-ACTING ANTIVIRAL-CONTAINING REGIMENS: THE MAGELLAN-I STUDY - Fred Poordad et al. -51st Annual Meeting of the European Association for the Study of the Liver Barcelona, Spain, 15 April 2016


Vuoi ricevere aggiornamenti su questo argomento? Iscriviti alla Newsletter!